Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Intratumoral KB707 (Cytokine Gene Therapy) in Gorlin Syndrome. The expected timing is based on the latest available company guidance and may change.
08/03/26:- OPAL-1 enrolled three Gorlin patients; interim update and plans expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.